Clinical trials: Lower Urinary Tract Symptoms (LUTS)
Prostatic Hyperplasia
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate.
- Trial name
- NCT00116571
- Testing
- Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
- Where
- 9 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- QLT Inc.
Benign Prostatic Hypertrophy
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy…
- Trial name
- NCT00427219
- Testing
- Ozarelix
- Where
- 13 sites in United States
- Volunteers
- 74 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Benign Prostatic Hyperplasia
MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia
Phase III, Randomized, double-blind, parallel placebo-controlled study. Two arms: MCS (30mg/day) vs. placebo. Subproject MCS-2: alpha-blocker naïve subjects Subproject MCS-3: subjects responding poorly to alpha-blocker
- Trial name
- NCT00501371
- Testing
- MCS
- Where
- 5 sites in Taiwan
- Volunteers
- 85 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Urinary Bladder, Overactive
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder.
- Trial name
- NCT00479505
- Testing
- UK-369,003
- Where
- 52 sites in Australia, Canada and 14 more
- Volunteers
- 275 people
- Sponsor
- Pfizer
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device.
- Trial name
- Omega (NCT05757687)
- Testing
- Omega device
- Where
- 5 sites in Georgia
- Volunteers
- 11 people
- Sponsor
- ProArc Medical
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- Trial name
- NCT02972268
- Testing
- Tamsulosin 0.2mg + Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 780 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
BPH (Benign Prostatic Hyperplasia)
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up…
- Trial name
- NCT07538622
- Testing
- Zenflow Spring System
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Zenflow, Inc.
Hyperplasia
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.
- Trial name
- NCT01203371
- Testing
- Naftopidil, Tamsulosin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Benign Prostatic Hyperplasia
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Trial name
- NCT01438775
- Testing
- NX-1207
- Where
- 28 sites in United States
- Volunteers
- 192 people
- Sponsor
- Nymox Corporation
Lower Urinary Tract Symptoms
Study to Evaluate Efficacy and Safety of NDS-446 in Men With Lower Urinary Tract Symptoms (LUTS)
Prospective, Randomized, Double-Blind, Placebo Controlled clinical trial to study the efficacy and the safety of NDS-446 (500 mg/cap) in Men 45 years of age or older with moderate to severe lower urinary tract symptoms (LUTS)
- Trial name
- NCT02808013
- Testing
- NDS-446
- Volunteers
- 116 people
- Sponsor
- Naturex-Dbs
Lower Urinary Tract Symptoms
Reliability of Home Uroflowmetery Using a Disposable Digital Device
The FloRite™ device is a disposable urine flow meter, indicated for use in a home setting. The device provides Urofowmetry measurements, similar to clinic's measurements.
- Trial name
- NCT02026674
- Testing
- FloRite
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Flometrica Ltd.
Urethral Stricture
ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
ROBUST III is a prospective, multi-center, randomized controlled adaptive sample size clinical trial to establish the safety and effectiveness for the Optilume Stricture Drug Coated Balloon (DCB).
- Trial name
- ROBUST-III (NCT03499964)
- Testing
- Optilume Drug Coated Balloon (DCB), Control Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Urotronic Inc.
LUTS, Benign Prostatic Hyperplasia
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02447367
- Testing
- JLP-1207(Fasted), JLP-1207(Fed)
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Impotence
Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.
- Trial name
- NCT00143221
- Testing
- Viagra
- Volunteers
- 350 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Lower Urinary Tract Symptoms (LUTS)
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- DELUTS (NCT00947882)
- Testing
- Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 404 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device.
- Trial name
- NCT02326454
- Testing
- talaporfin sodium, Saline, Drug Activator 100 J/cm
- Where
- 41 sites in United States
- Volunteers
- 225 people
- Sponsor
- Light Sciences Oncology
Non-muscle Invasive Bladder Cancer (NMIBC)
Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.
This will be an open-label, prospective, single-centre, randomised, controlled, parallel-group medical device investigation. The investigational plan will include four visits in total at the investigational site.
- Trial name
- NCT06069453
- Testing
- Hyaluronic Acid (HA) sodium salt and Hydeal-D
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fidia Farmaceutici s.p.a.